investors can Contact the law firm for free to learn more about recovering their losses

LOS ANGELES, Jan. 5, 2023 (GLOBE NEWSWIRE) — The law firm of Portnoy advises Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) FAT Investors that the law firm has opened an investigation on behalf of investors who lost money on their Phathom Pharmaceuticals, Inc. stock. Phathom Pharmaceuticals, Inc. investors are encouraged to do so Contact the company to discuss their legal rights.

Investors are encouraged to contact an attorney Lesley F Portnoyby phone 844-767-8529 or E-mail: lesley@portnoylaw.comto discuss your legal rights, or click here to join the case about www.portnoylaw.com. Portnoy Law Firm can provide a free case assessment and discuss investors’ options for making claims to recover their losses.

On January 3, 2022, Phathom issued a press release announc[ing] that the U.S. Food and Drug Administration (FDA) has notified the Company that it has taken no action with respect to the Company’s New Drug Application (NDA) for Vonoprazan, a novel potassium-competitive acid blocker (PCAB) being evaluated for the treatment of erosions esophagitis, on or before the current Prescription Drug User Fee Act (PDUFA) action date of January 11, 2023.” The FDA’s decision came after Phathom announced on August 2, 2022, “that it had detected trace amounts of a nitrosamine impurity, N-nitroso-vonoprazan (NVP) in commercial batches and worked closely with the FDA to obtain approval of a proposed acceptable daily intake limit, testing procedure and controls to address this impurity before vonoprazan-based products were placed on the market Phathom further stated that “the FDA has requested additional stability data, di e show that the NVP levels stay below [the acceptable daily intake] Limitation during the proposed shelf life of the product.”

As a result of this news, Phathom’s stock price fell $3.73 per share, or 31.11%, to close at $8.26 per share on January 4, 2023.

You’re welcome…